By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Key Statistics

Email: n/a
Ownership: Public

Web Site: AmpliPhi Biosciences Corporation
Symbol: APHB


Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.

Company News
AmpliPhi Biosciences Corporation (APHB) Announces Award Of Federal Research Grant From Australia To Its Collaboration Partner, Westmead Institute 2/9/2016 8:47:13 AM
AmpliPhi Biosciences Corporation (APHB) Announces Dosing Of First Patient In Phase I Clinical Trial Of AB-SA01 1/20/2016 8:11:45 AM
AmpliPhi Biosciences Corporation (APHB) Announces Appointment Of Steve R. Martin As Chief Financial Officer 1/19/2016 8:15:11 AM
AmpliPhi Biosciences Corporation (APHB) Acquires Key Bacteriophage Assets From UK-based Novolytics 1/8/2016 8:17:12 AM
AmpliPhi Biosciences Corporation (APHB) Signs Clinical Trial Agreement With University of Adelaide To Conduct A Phase I Trial Of Bacteriophage Therapy For Treating Staphylococcus Aureus Infections 11/19/2015 10:24:07 AM
AmpliPhi Biosciences Corporation (APHB) Announces Board Expansion With Appointment Of Two Highly-Experienced Non-Executive Directors 11/10/2015 11:33:58 AM
AmpliPhi Biosciences Corporation (APHB)’s Chief Executive Officer, M. Scott Salka, Gives Interview To The Wall Street Transcript 10/23/2015 10:01:57 AM
AmpliPhi Biosciences Corporation (APHB) Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model 9/21/2015 11:43:31 AM
AmpliPhi Biosciences Corporation (APHB) To Present At Rodman & Renshaw 17th Annual Global Investment Conference 9/8/2015 11:25:26 AM
AmpliPhi Biosciences Corporation (APHB) Announces Appointment Of Alexander Gaidamaka As Vice President Of Chemistry, Manufacturing And Control 9/3/2015 9:20:03 AM